Loading...
Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle
Vx-770 (Ivacaftor), a Food and Drug Administration (FDA)-approved drug for clinical application to patients with cystic fibrosis (CF), shifts the paradigm from conventional symptomatic treatments to therapeutics directly tackling the root of the disease: functional defects of the cystic fibrosis tra...
Na minha lista:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
National Academy of Sciences
2013
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3600496/ https://ncbi.nlm.nih.gov/pubmed/23440202 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1215982110 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|